Bristol Myers Squibb announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the Eur...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...
Aragen is pleased to announce that its Formulation Manufacturing Facility (FMF) has been awarded Good Manufacturing Practice (GMP) certification by the Dru...
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...
Selvita S.A. announced completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes ...
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced the launch of Epidemiology Intelligence™. The new sol...
Astellas Pharma and Poseida Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therape...
German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biop...
Sandoz, a global leader in generic and biosimilar medicines, is pleased to announce the European Commission's (EC) approval of Pyzchiva® (biosimilar us...
The quest for efficiency without compromising safety and compliance is paramount. This was the central theme of the panel discussion titled "Reimag...
© 2024 Biopharma Boardroom. All Rights Reserved.
